Literature DB >> 22555894

The effects of systemic, topical, and intralesional steroid treatments on apoptosis level of nasal polyps.

Burak Kapucu1, Engin Cekin, Bulent Evren Erkul, Hakan Cincik, Atila Gungor, Ufuk Berber.   

Abstract

OBJECTIVE: The purpose of this study was to compare the apoptotic responses to systemic, topical, and intrapolyp injection of glucocorticoid with no treatment in nasal polyps. STUDY
DESIGN: Prospective, randomized controlled study.
SETTING: Tertiary training hospital. SUBJECTS AND METHODS: The study was performed on 48 patients with nasal polyposis in the Department of Otorhinolaryngology between 2008 and 2009. Patients were assigned to 1 of 4 groups of 12 patients. Group A was treated with oral methylprednisolone 1 mg/kg/d, and the dose was tapered gradually. Group B received 0.3 mL triamcinolone acetonide (40 mg/mL), which was injected into polyp tissue. Group C was treated with topical 55 µg triamcinolone acetonide 2 times daily for 1 month. Group D received no medication. Samples were collected endoscopically after the seventh day for groups A and B, the first month for group C, and the first visit for group D. Apoptotic indexes were determined using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling method.
RESULTS: Statistically significant differences in apoptotic index were found between each steroid-medicated group and the control group (P (D-A) = .0001; P (D-B) = .003; P (D-C) = .026) and between groups A and C (P (A-C) = .012). Group B did not differ significantly from either group A or C (P (A-B) = .11; P (B-C) = .75).
CONCLUSIONS: The apoptotic index in nasal polyps treated with systemic, topical, and intrapolyp injection forms of glucocorticoids was higher than that in the control group. Systemic steroid treatment induced the most apoptosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22555894     DOI: 10.1177/0194599812446678

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  Effect of distribution of nasal polyps in ostiomeatal complex on long-term outcomes after endoscopic surgery.

Authors:  Cheng Zhong; Zhendong Jiang; Xueyuan Zhang
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-11       Impact factor: 2.503

Review 2.  Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis.

Authors:  Karen Head; Lee Yee Chong; Claire Hopkins; Carl Philpott; Anne G M Schilder; Martin J Burton
Journal:  Cochrane Database Syst Rev       Date:  2016-04-26

Review 3.  Short-course oral steroids alone for chronic rhinosinusitis.

Authors:  Karen Head; Lee Yee Chong; Claire Hopkins; Carl Philpott; Martin J Burton; Anne G M Schilder
Journal:  Cochrane Database Syst Rev       Date:  2016-04-26

Review 4.  Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis.

Authors:  Lee Yee Chong; Karen Head; Claire Hopkins; Carl Philpott; Anne G M Schilder; Martin J Burton
Journal:  Cochrane Database Syst Rev       Date:  2016-04-26

5.  Topical Dexamethasone Administration Impairs Protein Synthesis and Neuronal Regeneration in the Olfactory Epithelium.

Authors:  Umberto Crisafulli; André M Xavier; Fabiana B Dos Santos; Tavane D Cambiaghi; Seo Y Chang; Marimélia Porcionatto; Beatriz A Castilho; Bettina Malnic; Isaias Glezer
Journal:  Front Mol Neurosci       Date:  2018-03-06       Impact factor: 5.639

Review 6.  Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper.

Authors:  Valerie Hox; Evelijn Lourijsen; Arnout Jordens; Kristian Aasbjerg; Ioana Agache; Isam Alobid; Claus Bachert; Koen Boussery; Paloma Campo; Wytske Fokkens; Peter Hellings; Claire Hopkins; Ludger Klimek; Mika Mäkelä; Ralph Mösges; Joaquim Mullol; Laura Pujols; Carmen Rondon; Michael Rudenko; Sanna Toppila-Salmi; Glenis Scadding; Sophie Scheire; Peter-Valentin Tomazic; Thibaut Van Zele; Martin Wagemann; Job F M van Boven; Philippe Gevaert
Journal:  Clin Transl Allergy       Date:  2020-01-03       Impact factor: 5.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.